FDA Clears Third COVID-19 Vaccine From Janssen
Emergency use authorization for single-dose vaccine that uses unique adenovirus type 26 delivery system for DNA code to reduce severity of coronavirus
March 1, 2021 The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The EUA issued Feb . 27, allows the Janssen Biotech COVID-19 Vaccine to be distributed in the U.S for use in individuals 18 years of age and older.
This vaccine is unique in that it only requires a single dose. The previously EUA cleared vaccines from Moderna and Pfizer required two doses. The Janssen vaccinator also in unique in its novel use of a modified adenovirus type 26 (Ad26) to safely deliver a piece of DNA to protect the patient from COVID infection.
FDA Approved Second COVID-19 Vaccine From Moderna
The FDA December 18 issued an emergency use authorization (EUA) for a second COVID-19 vaccine from Moderna for use in individuals 18 years of age and older.
December 23, 2020 The U.S. Food and Drug Administration December 18 issued an emergency use authorization (EUA) for a second vaccine for the prevention of coronavirus disease 2019 (COVID-19). The emergency use authorization allows the Moderna COVID-19 Vaccine to be distributed in the U.S. for use in individuals 18 years of age and older.
“With the availability of two vaccines now for the prevention of COVID-19, the FDA has taken another crucial step in the fight against this global pandemic that is causing vast numbers of hospitalizations and deaths in the United States each day,” said FDA Commissioner Stephen M. Hahn, M.D.
FDA Approves Second COVID-19 Vaccine From Moderna
December 23, 2020 The U.S. Food and Drug Administration December 18 issued an emergency use authorization (EUA) for a second vaccine for the prevention of coronavirus disease 2019 (COVID-19). The emergency use authorization allows the Moderna COVID-19 Vaccine to be distributed in the U.S. for use in individuals 18 years of age and older.
“With the availability of two vaccines now for the prevention of COVID-19, the FDA has taken another crucial step in the fight against this global pandemic that is causing vast numbers of hospitalizations and deaths in the United States each day,” said FDA Commissioner Stephen M. Hahn, M.D.